NCT01372358

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions

Single Dose, Randomized, Two-period, Two-treatment, Two-sequence Crossover Relative Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets Under Non-Fasting Condition.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Dr. Reddy's Laboratories Limited · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to compare the relative bioavailability of ciprofloxacin 1000 mg ER tablets of Dr.Reddy's with that of CIPRO® XR 1000 mg of Bayer Pharmaceuticals Corporation in healthy, adult, non-smoking subjects under non-fasting conditions.

Detailed description

This single dose, randomized, two-period, two-treatment, two sequence crossover study was conducted to compare the relative bioavailability of ciprofloxacin 1000 mg ER tablets of Dr. Reddy's and CIPRO® XR 1000 mg of Bayer Pharmaceuticals Corporation under non-fasting conditions.

Conditions

• Fed

Interventions

Type	Name	Description
DRUG	CIPRO®XR	Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited

Timeline

• Start date: 2005-01-01
• Primary completion: 2005-01-01
• Completion: 2005-02-01
• First posted: 2011-06-13
• Last updated: 2011-06-13

Locations

1 site across 1 country: United States